The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells

British Journal of Cancer

Volumn 81, Issue 6, 1999, Pages 942-951

  Traunecker, H C L ^a   Stevens, M C G ^b   Kerr, D J ^a   Ferry, D R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

GF120918; MES Dx5 cells; Multidrug resistance; P glycoprotein inhibitor

Indexed keywords

ACRIDINE DERIVATIVE; AMIDE; CARBON 14; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; PACLITAXEL; TRITIUM; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; SARCOMA CELL;

ACRIDINES; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOQUINOLINES; P-GLYCOPROTEIN; SARCOMA; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 0032742906     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690791     Document Type: Article

References (34)

1. Barrand MA, Heppel-Parton AC, Wright KA, Rabbits PH and Twentyman PR (1994) A 190k protein overexpressed in non-P-glycoprotein containing MDR cells and its relation to the MRP gene. J Natl Cancer Inst 86: 110-117
2. Boer R, Dichil M, Borchers C, Ulrich WR, Marecek JF, Prestwich GD, Glossmann H and Striessing J (1996) Reversible labeling of a chemosensitizer binding domain of P-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor. Biochemistry 35: 1387-1396
3. Callaghan R, Berridge G. Ferry DR and Higgins CF (1997) The functional purification of P-glycoprotein is dependent on maintenance of a lipid protein inter-face. Biochem Biophys Acta Biomembranes 1328: 109-124
4. Chen G, Jaffrezou J-P, Fleming WH, Duran GE and Sikie BI (1994) Prevalence of multidrug resistance related to activation of the mdrl gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 54: 4980-4987
5. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz E, Duncan AMV and Deeley RG (1992) Over-expression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1653
6. Davies R, Budworth J, Riley J, Snowden R, Gescher A and Gant T (1996) Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF 7/Dox cell line subclones. Br J Cancer 73: 307-315
7. Day S, Ramachandra M, Pastan I, Gottesman MM and Ambudkar SV (1997) Evidence for two non-identical drug-interaction sites in the human P glycoprotein. Proc Natl Acad Sci USA 94: 10594-10599
8. DeLean A, Hancock AA and Lefkowitz RJ (1981) Validation and statistical analysis of a computer modelling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 21: 5-16
9. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58: 137-171
10. Ferry DR, Russell MA and Cullen MH (1992) P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca alkaloid-selective binding site. Biochem Biophys Res Commun 188: 440-445
11. 3H]-Taxol binds to a drug acceptor site which is allosterically coupled to the vinblastine-selective site of P-glycoprotein. Proc Am Assoc Cancer Res 35: 348
12. 3H] - vinblastine binding to P-glycoprotein of MCF-7 ADR breast cancer cell membranes. Biochem Pharmacol 49: 1851-1861
13. 3H] vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldípine. Biochem Pharmacol 49: 1851-1861
14. 3H]-GG918 (GF120918) binds with positive co-operativity to human P glycoprotein with a nM dissociation constant. Proc Am Assoc Cancer Res 37: abstract 2246
15. Ferry D, Moore M, Bartlett NL, Fyfe D, Oza G, Fracasso PM, Kersey K, Wissel PS, Jewell RC and Paul EM (1998) Phase 1 and pharmacokinetic (PK) study targeting a 500 ng/ml plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (DOX) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 240a
16. Ford JM and Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42(3): 155-199
17. Gosland MP, Lum BL and Sikic BI (1989) Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma line. Cancer Res 49: 6901-6905
18. Gottesman MM and Pastan P (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427
19. Harker WG and Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin selected variants of the human sarcoma cell line MES-SA. Cancer Res 45: 4091-4096
20. Harker WG, MacKintosh FR and Sikic BI (1983) Devlopment and characterization of a human sarcoma cell line, MES SA, sensitive to multiple drugs. Cancer Res 43: 4943-4950
21. Hyafil F, Vergely C, Du VP and Grand PT (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53(19); 4595-4602
22. Kajiji S, Dreslin JA, Grizzuti K and Gros P (1994) Structurally distinct MDR modulators show specific pattern of reversal against P glycoproteins bearing unique mutations at serine (939/941). Biochem 33(17): 5041-5048
23. Malkhandi PJ, Ferry DR, Boer R and Kerr DJ (1995) P-glycoprotein has a drug acceptor site for 1,4-dihydropyridines which is localised on an intracellular domain. Proc Am Assoc Cancer Res 36; 332
24. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Oncol 9: 17-24
25. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63
26. Planting A, van der Gaast A, Sparreboom A, van der Burg MEL, de Boer M, Wissel PS, Jewell RC, Paul EM and Verweij J (1998) Phase I and pharmacokinetic (PK) study targeting a 100 ng/ml plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (DOX) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 199a
27. Raviv Y, Poland HB, Bruggermann EP, Pastan I and Gottesman MM (1990) Photosensitive labeling of a functional multidrug transporter in living drug resistant tumour cells. J Biol Chem 265: 3975-3980
28. Sambrook J, Fritsch EF and Maniatis T (1989). Transfer of proteins from SDS polyacrylamide gels to solid supports: immunological detection of immobilized proteins (Western blotting). In: Laboratory Cloning a Laboratory Manual, Nolan C (ed), pp. 18.60-18.75. Cold Spring Harbor Laboratory Press: New York
29. L 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475-1479
30. Schibler MJ and Cabral F (1986) Taxol-dependent mutants of chinese hamster ovary cells with alterations in alpha-tubulin and beta-tubulin. J Cell Biol 102: 1522-1531
31. Shupiro AB, Ling V and Doige CA (1995) Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270: 16167-16175
32. Sonneveld P, Duric BGM, Lokhorst HM, Marie J-P, Solbu G, Zittoun R., Lowenberg B and Nooler K (1992) Modulation of multidrug resistant mycloma by cyclosporin. Lancet 340: 255-258
33. Spoelstra EC, Westerhoff HV, Dekker H and Lankelma J (1992) Kinetics of daunorubicin transport by P.glycoprotein of intact cells. Eur J Biochem 207: 567-579
34. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS and Wissel PS (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7-12